Literature DB >> 27730669

Highly pathogenic avian influenza H5N1 virus induces cytokine dysregulation with suppressed maturation of chicken monocyte-derived dendritic cells.

Semmannan Kalaiyarasu1, Manoj Kumar2, Dhanapal Senthil Kumar2, Sandeep Bhatia2, Sandeep Kumar Dash3, Sushant Bhat3, Rohit K Khetan2, Shanmugasundaram Nagarajan2.   

Abstract

One of the major causes of death in highly pathogenic avian influenza virus (HPAIV) infection in chickens is acute induction of pro-inflammatory cytokines (cytokine storm), which leads to severe pathology and acute mortality. DCs and respiratory tract macrophages are the major antigen presenting cells that are exposed to mucosal pathogens. We hypothesized that chicken DCs are a major target for induction of cytokine dysregulation by H5N1 HPAIV. It was found that infection of chicken peripheral blood monocyte-derived dendritic cells (chMoDCs) with H5N1 HPAIV produces high titers of progeny virus with more rounding and cytotoxicity than with H9N2 LPAIV. Expression of maturation markers (CD40, CD80 and CD83) was weaker in both H5N1 and H9N2 groups than in a LPS control group. INF-α, -β and -γ were significantly upregulated in the H5N1 group. Pro-inflammatory cytokines (IL-1β, TNF-α and IL-18) were highly upregulated in early mid (IL-1), and late (IL-6) phases of H5N1 virus infection. IL-8 (CXCLi2) mRNA expression was significantly stronger in the H5N1 group from 6 hr of infection. TLR3, 7, 15 and 21 were upregulated 24 hr after infection by H5N1 virus compared with H9N2 virus, with maximum expression of TLR 3 mRNA. Similarly, greater H5N1 virus-induced apoptotic cell death and cytotoxicity, as measured by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling and lactate dehydrogenase assays, respectively, were found. Thus, both H5N1 and H9N2 viruses evade the host immune system by inducing impairment of chMoDCs maturation and enhancing cytokine dysregulation in H5N1 HPAIV-infected cells.
© 2016 The Societies and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  avian influenza; chemokine; cytokine; monocyte-derived DC

Mesh:

Substances:

Year:  2016        PMID: 27730669     DOI: 10.1111/1348-0421.12443

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  6 in total

Review 1.  Potential role of biochemical markers in the prognosis of COVID-19 patients.

Authors:  Apeksha Niraula; Nirmal Baral; Madhab Lamsal; Mahima Bataju; Saroj Thapa
Journal:  SAGE Open Med       Date:  2022-07-05

2.  Perspectives on the use and risk of adverse events associated with cytokine-storm targeting antibodies and challenges associated with development of novel monoclonal antibodies for the treatment of COVID-19 clinical cases.

Authors:  Aishwarya Mary Johnson; Robert Barigye; Hariharan Saminathan
Journal:  Hum Vaccin Immunother       Date:  2021-05-11       Impact factor: 3.452

Review 3.  The COVID-19 Cytokine Storm; What We Know So Far.

Authors:  Dina Ragab; Haitham Salah Eldin; Mohamed Taeimah; Rasha Khattab; Ramy Salem
Journal:  Front Immunol       Date:  2020-06-16       Impact factor: 7.561

Review 4.  The Drivers of Pathology in Zoonotic Avian Influenza: The Interplay Between Host and Pathogen.

Authors:  William S J Horman; Thi H O Nguyen; Katherine Kedzierska; Andrew G D Bean; Daniel S Layton
Journal:  Front Immunol       Date:  2018-08-08       Impact factor: 7.561

Review 5.  Impact of cytokine storm and systemic inflammation on liver impairment patients infected by SARS-CoV-2: Prospective therapeutic challenges.

Authors:  Fares E M Ali; Zuhair M Mohammedsaleh; Mahmoud M Ali; Osama M Ghogar
Journal:  World J Gastroenterol       Date:  2021-04-21       Impact factor: 5.742

6.  Effects of Receptor Specificity and Conformational Stability of Influenza A Virus Hemagglutinin on Infection and Activation of Different Cell Types in Human PBMCs.

Authors:  Jens Dorna; Andreas Kaufmann; Viktoria Bockmann; Hartmann Raifer; Johanna West; Mikhail Matrosovich; Stefan Bauer
Journal:  Front Immunol       Date:  2022-03-14       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.